To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

November 02, 2017

Today's Rundown

Featured Story

Sanofi ditches IL-4/IL-13 antibody drug in lung-scarring disease

In Sanofi’s third-quarter results posted early this morning, the French Big Pharma says it is canning a phase 2 trial in idiopathic pulmonary fibrosis, following on poor results from Roche and AstraZeneca.

Top Stories

Agios’ data on leukemia drug ivosidenib doesn’t excite investors

Shares in Agios have fallen after a preview of ASH data that will be used to support an FDA filing for refractory acute myeloid leukemia candidate ivosidenib.

Aisling Capital raises $280M for life sciences work, down from previous funding

New York venture firm Aisling Capital has raised a solid chunk of cash for clinical-stage biotechs as it looks to build on some of its recent successes.

[Sponsored] Mitotech: a (very) different approach to treating Dry Eye

Approximately 16 million Americans have been told by their doctor that they have Dry Eye Disease – the itchy, uncomfortable and inconvenient condition that remains the number one reason people go see an ophthalmologist.

Chasing Biogen, AveXis posts improved gene therapy data

AveXis has posted an update on the spinal muscular atrophy patients treated with its gene therapy. The latest data show an uptick in the proportion of patients able to sit unassisted and talk, fueling AveXis’ hopes of establishing AVXS-101 as a rival to Biogen’s Spinraza.

Boehringer, Dicerna pen $201M pact to hit NASH with RNAi 

Boehringer Ingelheim has put up $201 million (€173 million) to work with Dicerna Pharmaceuticals on RNAi treatments for NASH and other chronic liver diseases. The goal is to use Dicerna’s GalXC technology to silence previously inaccessible drug targets, thereby restoring liver function.

PPD wins 7-year HIV research contract

Major CRO player Pharmaceutical Product Development (PPD) has won a lucrative seven-year government contract in infectious disease.

As Amazon entry into pharma looms, CEOs see plenty of room for change in distribution

Online retailing giant Amazon has yet to publicly disclose any plans to get into drug sales, but the mere speculation has pharma CEOs thinking, and speaking, about how it could entirely remake their world.

Enrollment Showcase

Online Graduate Programs Designed for Your Career

Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more.

Resources

[Whitepaper] Meeting the Challenge of Appropriate Safety Report Distribution

As clinical trials become more complex, safety document distribution to investigative sites has reached the point that demands a solution.

[Whitepaper] Institutionalizing Real-World Evidence

In the quest to understand how a therapeutic intervention performs in actual use – in real medical practice outside the controlled environment of clinical trials – many life sciences organizations are stymied. Download now to read more.

[Webinar] Tips to escape the Vacancy Trap and avoid it entirely

December 5, 2017 | 2pm EST / 11am PST: Join this webinar to discover tested and proven solutions to manage vacancies. Presented by Tyler Cowan, VP, Client Solutions, Ashfield US, you’ll learn how to maintain and build momentum in field sales despite turnover.

[Whitepaper] Veeva 2017 Annual CRO Report: CROs lead the drive to a unified clinical model

CROs are leading an industry wide shift to modernize clinical systems and clinical trial processes.

[Webinar] Validating a 7 Day Membrane Filtration Sterility Test using Celsis®

Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols.

[Infographic] Evolution of Flexible Commercial Biologics Manufacturing

Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility.

[eBook] Developing Site-specifically Modified ADCs: Using a Chemoenzymatic Approach

Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology.

[Article] Optimizing titer and use of a specific enzyme for generating a fully processed antibody

Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing.

[Webinar] Within-Subject Clinical Trials: Intro to New Methods & Stat. Models

In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods.

Events

.